Preferred Label : Fuzuloparib;
NCIt synonyms : 4-((3-((5,6-Dihydro-2-(trifluoromethyl)(1,2,4)triazolo(1,5-a)pyrazin-7(8H)-yl)carbonyl)-4-fluorophenyl)methyl)-1(2H)-phthalazinone; Fluzoparib;
NCIt definition : An orally available inhibitor of poly (ADP-ribose) polymerase (PARP) types 1 and 2,
with potential antineoplastic activity. Upon oral administration, fuzuloparib inhibits
PARP 1 and 2 activity, which inhibits PARP-mediated repair of damaged DNA via the
base excision repair (BER) pathway, enhances the accumulation of DNA strand breaks,
promotes genomic instability, and leads to an induction of apoptosis. The PARP family
of proteins catalyze post-translational ADP-ribosylation of nuclear proteins, which
then transduce signals to recruit other proteins to repair damaged DNA. PARP inhibition
may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance
and radioresistance.;
UNII : TWF0ML1CK8;
InChIKey : XJGXCBHXFWBOTN-UHFFFAOYSA-N;
CAS number : 1358715-18-0; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1358715-18-0
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Drug name : AiRuiYi;
Molecule name : SHR-3162;
NCI Metathesaurus CUI : CL504851;
Origin ID : C126274;
UMLS CUI : C4289267;
Semantic type(s)
- UMLS correspondences (same concept)
- chemical_or_drug_affects_gene_product
- concept_is_in_subset
- has_target
